FDA approves former Eli Lilly candidate that delays type 1 diabetes onset
US-based Provention Bio has succeed in bringing a former Eli Lilly candidate that delays type 1 diabetes progression to market.
by christopher due karlsson, translated by daniel pedersen
The US Food and Drug Administration, FDA, has given its regulatory nod to Tzield, which was submitted for review by US-based biotech company Provention Bio and is based on the former Eli Lilly antibody teplizumab.
In Jyske Bank’s eyes, Genmab’s newest cancer candidate is almost certain to be approved, though the bank says stock increases in the past year have reduced the upside potential for the Danish biotech firm.
The US retail chain has stopped selling its own private label hearing aids – and until the next generation comes along, other hearing companies selling products via Costco are enjoying the empty shelf space.